Carriers of pathogenic variants in BRCA1 or BRCA2 are at significantly increased risk (Relative Risk (RR) > 4) for breast and ovarian cancer and this knowledge can guide screening for early detection and the use of risk-reducing prophylactic surgeries. The gene discussed is BRCA1; the disease is ovarian carcinoma.